Results 101 to 110 of about 6,506,258 (188)
Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
Nishanth Vallumsetla, Jonas Paludo, Prashant Kapoor Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA Abstract: Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma ...
Paludo J, Kapoor P, Vallumsetla N
core
Ibrutinib plus Venetoclax May Be Effective in Mantle-Cell Lymphoma
Ibrutinib plus venetoclax is superior to monotherapy in patients with mantle-cell lymphoma.
core +1 more source
[Cytogenetics of mantle cell lymphoma].
To determine the type and rate of secondary chromosomal aberrations and role in pathogenesis of mantle cell lymphoma (MCL).Standard cytogenetic examination (SCE) and fluorescent in situ hybridization (FISH) with tests for 11q22/ATM, 13q14, 17p13/p53, 9p21/p16 and chromosome 12 centromere were made in 28 patients.Secondary chromosomal aberrations were ...
T N Obukhova +7 more
openaire +2 more sources
Endotracheal Involvement as an Unusual Extranodal Site of Recurrence from Mantle
Mantle cell lymphomas are uncommon subtypes of non-Hodgkin’s lymphoma with poor overall survival ranging from 3-5 years. Patients are often middle aged men who would present with generalized lymphadenopathy and typical constitutional symptoms. Extranodal
Ann Mcgeehan +2 more
core
Collision tumors composed of colorectal adenocarcinoma and mantle cell lymphoma are exceptionally rare, and component-resolved molecular characterization is largely lacking. We report a 65-year-old woman who initially presented with rectal adenocarcinoma
Qing Zhang +3 more
doaj +1 more source
Pulmonary mantle cell lymphoma: a rare manifestation of an uncommon condition
Herein we describe the case of a 64-year old man with a history of mantle cell lymphoma found to have evidence of pulmonary parenchymal involvement by recurrence of his lymphoma.
Zachary S. DePew, Robert Vassallo
doaj +1 more source
ABSTRACT Introduction BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity.
Steven M. Bair +11 more
wiley +1 more source
Molecular Pathogenesis of MALT lymphoma [PDF]
Mucosa associated lymphoid tissue (MALT) lymphoma is characterized by t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH and t(14;18)(q32;q21)/IGH-MALT1, which commonly activate the NF-κB pathway.
core +2 more sources
ABSTRACT Concerns about treatment‐related fertility impairment are common among young adult lymphoma survivors. Evidence on the impact of treatment for aggressive non‐Hodgkin lymphoma (NHL) on future childbearing is limited, although many individuals of reproductive age are affected.
Stefanie Antonilli +10 more
wiley +1 more source
Can a single element help address the multifactorial nature of ALS? Boron‐containing compounds combine responsiveness to reactive oxygen species (ROS), neuroprotective activity, and favorable pharmacological properties, offering a distinctive framework for disease modification in a complex disease like ALS.
Nitesh Sanghai +5 more
wiley +1 more source

